Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gilead/Galapagos' Trailing JAK1 Filgotinib Boosted By AS Trial

Executive Summary

Gilead and Galapagos have more decent clinical data for filgotinib tucked under their belt as the JAK1 inhibitor shows benefit in another indication, ankylosing spondylitis, with a safety profile that remains reassuring.

Advertisement

Related Content

Galapagos Targets Liver Fibrosis With Evotec Deal
Finance Watch: Lilly Completes Elanco Animal Health Spin-Out As New IPO Filings Keep Rising
Rheumatoid Arthritis Data Position Filgotinib Ahead Of Competition, But It's Playing Catch-Up
AbbVie's New Generation JAK inhibitor Looks Good But CV Specter Looms

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123799

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel